Sustained, long-acting HIV prevention drugs for people at risk
Official title: Sustained Release of Potent Antiviral Prodrugs for HIV Prevention
Funded at Oak Crest Institute of Science · NIH-11421470 · Data updated 2026-11-12
A study is exploring long-acting HIV prevention drugs delivered in a way that could mean fewer injections or treatments for people at risk of HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oak Crest Institute of Science NIH-funded |
| Lab location | 1 site (Monrovia, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $808,442 |
| NIH project number | 5R01AI172541-04 |
| Project ID | NIH-11421470 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk of HIV exposure who would benefit from less frequent dosing and longer-acting prevention options.
✕Less likely to help
People who already have HIV or who would not be eligible for PrEP strategies may not benefit.
What this research studies
This project looks at delivering antiretroviral medications in a sustained-release form to prevent HIV infection, aiming to reduce how often people need to take medicine. It focuses on formulations that could provide protection for weeks to months and work well for diverse groups at risk in real-world settings. Researchers plan to test pharmacokinetics, safety, and how these long-acting options might fit into existing prevention strategies. The work builds on lessons from current PrEP approaches to address adherence and accessibility challenges.
Why it matters
Potential benefit: If successful, it could make HIV prevention easier and more consistent, reducing new infections.
How similar studies have gone: Long-acting PrEP approaches are advancing in the field, with ongoing exploration of safety and usability.
Where this research is happening
-
Oak Crest Institute of Science
Monrovia, United States Active
Researchers
- Principal investigator: Baum, Marc Michael — Oak Crest Institute of Science
- Study coordinator: Baum, Marc Michael
Related research
Other NIH-funded projects on the same topics.
-
Making HIV prevention and care easier for Ugandan youth
A Ugandan study is testing ways to help adolescents and young adults (15–24) prevent HIV and stay healthy, using long-acting PrEP and youth-friendly services.
-
Innovative HIV Prevention and Care Interventions for Adolescents and Young Adults in Uganda
A Ugandan research team is testing practical, youth-focused strategies to help 15-24 year-olds using HIV prevention or treatment services stay healthy and engaged in care.
-
Adolescent girls in Uganda: a long-term look at how money empowerment and family support affect HIV prevention, care, and mental health
A long-term study in rural Uganda will test whether an intervention that combines economic empowerment and family strengthening can help HIV-negative and HIV-affected adolescent girls move safely into young adulthood.
-
Long-term HIV prevention and mental health support for adolescent girls and young women in Uganda
A long-term program in rural Uganda tests if combining economic support and family strengthening helps teenage girls stay HIV-free and improve mental health as they grow into young adults.
-
Harnessing male peer networks to boost HIV testing and PrEP use
A large clinical trial in South Africa tests whether giving HIV self-test kits through male peer networks, with phone support, increases PrEP uptake among men.
-
Harnessing men's peer networks to boost HIV self-testing and PrEP use
A large project in South Africa tests whether giving HIV self-test kits through men’s social networks, with phone support, can lead to more men starting PrEP and using HIV testing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.